SPOTLIGHT: FDA panel votes to restrict Ketek
An FDA advisory panel has voted to restrict the use of Sanofi-Aventis' controversial antibiotic Ketek. Panel members said that the risks outweighed the benefits of using Ketek against acute bacterial sinusitis and acute bacterial exacerbation of chronic bronchitis. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
